{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:47:42Z","timestamp":1785232062989,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Fibrosing, non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung diseases (fILDs) are a heterogeneous group of diseases characterized by a different amount of inflammation and fibrosis. Therapy is currently based on corticosteroids and\/or immunomodulators. However, response to these therapies is highly variable, sometimes without meaningful improvement, especially in more fibrosing forms. Pirfenidone and nintedanib have recently demonstrated to reduce functional decline in patients with IPF. However, their antifibrotic mechanism makes these two drugs an interesting approach for treatment of fibrosing ILDs other than IPF.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>We here report our experience with antifibrotic drugs in fibrosing non-IPF ILDs patients having a progressive phenotype during immunosuppressive therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Patients with a multidisciplinary team diagnosis of fibrosing non-IPF ILDs experiencing a progressive phenotype during treatment with corticosteroids and\/or immunomodulators between October-2014 and January-2018 at our tertiary referral Center for ILDs were retrospectively analyzed. Antifibrotic therapy was administered after application with the respective health insurance company and after consent by the patient. Pulmonary-function-tests and follow-up visits were performed every 6\u2009\u00b1\u20091\u2009months.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Eleven patients were treated with antifibrotic drugs (8 males, mean age 62\u2009\u00b1\u200912.8\u2009years, mean FVC% 62.8\u2009\u00b1\u200922.3, mean DLCO% 35.5\u2009\u00b1\u200910.7, median follow-up under antifibrotic treatment 11.1\u2009months). Patients had a diagnosis of unclassifiable ILD in 6 cases, pleuroparenchymal fibroelastosis in 2 cases, idiopathic-NSIP in 1 case, asbestos-related ILD in 1 case and Hermansky-Pudlak syndrome in 1 case. Treatment before antifibrotics consisted of corticosteroids in all patients: 5 combined with Azathioprin, 1 with either methotrexate or cyclophosphamide (i.v.). Ten patients were treated with pirfenidone (2403\u2009mg\/die) and 1 with nintedanib (300\u2009mg\/die). Median FVC was 56, 56, 50%, at time points\u2009\u2212\u200924, \u2212\u200912, \u2212\u20096 before initiation, 44% at time of initiation and 46.5% at 6\u2009months after initiation of antifibrotic treatment. Antifibrotic treatment was generally well tolerated with a need of dose reduction in 2 cases (rash and nausea) and early termination in 3 cases.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Antifibrotic treatment may be a valuable treatment option in patients with progressive fibrosing non-IPF ILD if currently no other treatment options exist. However, prospective, randomized clinical trials are urgently needed to assess the real impact of antifibrotic therapy in these patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12890-019-0937-0","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T17:04:27Z","timestamp":1573578267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases"],"prefix":"10.1186","volume":"19","author":[{"given":"Sebastiano Emanuele","family":"Torrisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"W\u00e4lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilab","family":"Sarmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Polke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehler","family":"Lars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Eichinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Peter","family":"Heussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Palmucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Sambataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Sambataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Sambataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Vancheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"issue":"6","key":"937_CR1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"937_CR2","first-page":"79","volume-title":"Respiratory epidemiology","author":"D Valeyre","year":"2014","unstructured":"Valeyre D, Duchemann B, Nunes H, et al. Interstitial lung diseases. In: Annesi-Maesano I, Lundb\u00e4ck B, Viegi G, editors. Respiratory epidemiology; 2014. p. 79\u201387."},{"key":"937_CR3","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"key":"937_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1055\/s-0036-1580693","volume":"37","author":"S Puglisi","year":"2016","unstructured":"Puglisi S, Torrisi SE, Giuliano R, Vindigni V, Vancheri C. What we know about the pathogenesis of idiopathic pulmonary fibrosis. Semin Respir Crit Care Med. 2016;37:358\u201367.","journal-title":"Semin Respir Crit Care Med"},{"key":"937_CR5","doi-asserted-by":"publisher","first-page":"e000212","DOI":"10.1136\/bmjresp-2017-000212","volume":"4","author":"KR Flaherty","year":"2017","unstructured":"Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017;4:e000212.","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"937_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12890-017-0462-y","volume":"17","author":"J Behr","year":"2017","unstructured":"Behr J, Neuser P, Prasse A, Kreuter M, Rabe K, Schade-Brittinger C, et al. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, doubleblind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulm Med. 2017;17(1):122.","journal-title":"BMC Pulm Med"},{"key":"937_CR7","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.151322","volume":"43","author":"D Khanna","year":"2016","unstructured":"Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol. 2016;43:1672\u20139.","journal-title":"J Rheumatol"},{"issue":"Suppl. 106","key":"937_CR8","first-page":"75","volume":"35","author":"O Distler","year":"2017","unstructured":"Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS). Clin Exp Rheumatol. 2017;35(Suppl. 106):75\u201381.","journal-title":"Clin Exp Rheumatol"},{"issue":"150","key":"937_CR9","doi-asserted-by":"publisher","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","volume":"27","author":"V Cottin","year":"2018","unstructured":"Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076.","journal-title":"Eur Respir Rev"},{"key":"937_CR10","doi-asserted-by":"publisher","first-page":"PA3030","DOI":"10.1183\/13993003.congress-2018.PA3030","volume":"52","author":"A Olson","year":"2018","unstructured":"Olson A, Hartmann N, Schlenker-Herceg R, Wallace L. Prevalence of progressive fibrosing interstitial lung disease. Eur Respir J. 2018;52:PA3030. https:\/\/doi.org\/10.1183\/13993003.congress-2018.PA3030.","journal-title":"Eur Respir J"},{"key":"937_CR11","first-page":"A4273","volume":"197","author":"M Kreuter","year":"2018","unstructured":"Kreuter M, Olson A, Fischer A, Bendstrup E, Mounir B, Zouad-Lejour L, et al. Current treatment of patients with non-IPF progressive fibrosing interstitial lung disease. Am J Respir Crit Care Med. 2018;197:A4273.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9779","key":"937_CR12","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760\u20139.","journal-title":"Lancet"},{"issue":"22","key":"937_CR13","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"1","key":"937_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/13993003.00026-2015","volume":"47","author":"PW Noble","year":"2016","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243\u201353.","journal-title":"Eur Respir J"},{"key":"937_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079\u201387.","journal-title":"N Engl J Med"},{"issue":"22","key":"937_CR16","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"145","key":"937_CR17","doi-asserted-by":"publisher","first-page":"170053","DOI":"10.1183\/16000617.0053-2017","volume":"26","author":"Sebastiano Emanuele Torrisi","year":"2017","unstructured":"Torrisi SE, Pavone M, Vancheri A, Vancheri C. When to start and when to stop antifibrotic therapies. Eur Respir Rev. 2017. https:\/\/doi.org\/10.1183\/16000617.0053-2017.","journal-title":"European Respiratory Review"},{"key":"937_CR18","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/art.38702","volume":"66","author":"EL Herzog","year":"2014","unstructured":"Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheum. 2014;66:1967\u201378.","journal-title":"Arthritis Rheum"},{"key":"937_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/MCP.0000000000000408","volume":"23","author":"M Kreuter","year":"2017","unstructured":"Kreuter M, Walscher J, Behr J. Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?). Curr Opin Pulm Med. 2017;23:418\u201325.","journal-title":"Curr Opin Pulm Med"},{"key":"937_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1183\/09059180.00005512","volume":"22","author":"JJ Solomon","year":"2013","unstructured":"Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev. 2013;22:6\u201319.","journal-title":"Eur Respir Rev"},{"issue":"150","key":"937_CR21","doi-asserted-by":"publisher","first-page":"180074","DOI":"10.1183\/16000617.0074-2018","volume":"27","author":"L Richeldi","year":"2018","unstructured":"Richeldi L, Varone F, Bergna M, de Andrade J, Falk J, Hallowell R, et al. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018;27(150):180074.","journal-title":"Eur Respir Rev"},{"key":"937_CR22","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46:976\u201387.","journal-title":"Eur Respir J"},{"issue":"148","key":"937_CR23","doi-asserted-by":"publisher","first-page":"170139","DOI":"10.1183\/16000617.0139-2017","volume":"27","author":"G Sambataro","year":"2018","unstructured":"Sambataro G, Sambataro D, Torrisi SE, Vancheri A, Pavone M, Rosso R, et al. State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances. Eur Respir Rev. 2018;27(148):170139. https:\/\/doi.org\/10.1183\/16000617.0139-2017.","journal-title":"Eur Respir Rev"},{"key":"937_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.rmed.2019.03.011","volume":"150","author":"G Sambataro","year":"2019","unstructured":"Sambataro G, Sambataro D, Torrisi SE, Vancheri A, Colaci M, Pavone M, et al. Clinical, serological and radiological features of a prospective cohort of interstitial pneumonia with autoimmune features (IPAF) patients. Respir Med. 2019;150:154\u201360.","journal-title":"Respir Med"},{"issue":"6","key":"937_CR25","doi-asserted-by":"publisher","first-page":"e0130653","DOI":"10.1371\/journal.pone.0130653","volume":"10","author":"D Colombi","year":"2015","unstructured":"Colombi D, Dinkel J, Weinheimer O, Obermayer B, Buzan T, Nabers D, et al. Visual vs fully automatic histogram-based assessment of idiopathic pulmonary fibrosis (IPF) progression using sequential multidetector computed tomography (MDCT). PLoS One. 2015;10(6):e0130653.","journal-title":"PLoS One"},{"issue":"3","key":"937_CR26","doi-asserted-by":"publisher","first-page":"1801587","DOI":"10.1183\/13993003.01587-2018","volume":"53","author":"SE Torrisi","year":"2019","unstructured":"Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, et al. The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicenter observational study. Eur Respir J. 2019;53(3):1801587. https:\/\/doi.org\/10.1183\/13993003.01587-2018.","journal-title":"Eur Respir J"},{"issue":"1","key":"937_CR27","doi-asserted-by":"publisher","first-page":"e000289","DOI":"10.1136\/bmjresp-2018-000289","volume":"5","author":"TM Maher","year":"2018","unstructured":"Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respir Res. 2018;5(1):e000289.","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"937_CR28","first-page":"161","volume":"44","author":"AC Duarte","year":"2019","unstructured":"Duarte AC, Vinagre F, Soares J, Cordeiro A. Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome. Acta Reumatol Port. 2019;44(2):161\u20132.","journal-title":"Acta Reumatol Port"},{"issue":"2","key":"937_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00408-019-00203-w","volume":"197","author":"D Bennett","year":"2019","unstructured":"Bennett D, Refini RM, Valentini ML, Fui A, Fossi A, Pieroni M. T al. Pirfenidone therapy for familial pulmonary fibrosis: a real-life study. Lung. 2019;197(2):147\u201353.","journal-title":"Lung"},{"issue":"1\u20132","key":"937_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ymgme.2018.07.012","volume":"125","author":"KJ O'Brien","year":"2018","unstructured":"O'Brien KJ, Introne WJ, Akal O, Akal T, Barbu A, McGowan MP, et al. Prolonged treatment with open-label pirfenidone in Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab. 2018;125(1\u20132):168\u201373.","journal-title":"Mol Genet Metab"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-019-0937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-019-0937-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-019-0937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:11:20Z","timestamp":1605053480000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-019-0937-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1186\/s12890-019-0937-0","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]},"assertion":[{"value":"26 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics committee of the University of Heidelberg approved this retrospective study. Due to the retrospective nature of this analysis and according to the vote of the ethics committee, written informed consent could not be obtained by the patients but patient records \/ information were anonymized and de-identified prior to analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.E. Torrisi reports grants from Boehringer Ingelheim and F Hoffman La-Roche, outside the submitted work. J. W\u00e4lscher reports fees for consulting from Boehringer Ingelheim and Roche\/InterMune, outside the submitted work. C. Vancheri reports grants and speaker\u2019s fees from Boehringer Ingelheim and Intermune\/F Hoffman La-Roche, outside the submitted work. M. Kreuter reports grants and fees for consulting from Boehringer Ingelheim and Roche\/InterMune, outside the submitted work. The other authors report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}